Revelation Biosciences Files 8-K
Ticker: REVBW · Form: 8-K · Filed: May 16, 2024 · CIK: 1810560
| Field | Detail |
|---|---|
| Company | Revelation Biosciences, Inc. (REVBW) |
| Form Type | 8-K |
| Filed Date | May 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $12,075.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, financial-reporting, sec-filing
Related Tickers: REVB
TL;DR
REVB filed an 8-K on 5/15/24 covering shareholder votes and financials.
AI Summary
Revelation Biosciences, Inc. filed an 8-K on May 15, 2024, reporting on matters submitted to a vote of security holders and filing financial statements and exhibits. The company, formerly known as Petra Acquisition Inc., is incorporated in Delaware and based in San Diego, California.
Why It Matters
This filing indicates corporate actions and financial reporting updates for Revelation Biosciences, Inc., which could impact investors' understanding of the company's status.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate actions and financial statements, not indicating immediate significant financial distress or major strategic shifts.
Key Numbers
- 001-39603 — SEC File Number (Identifies the company's filing history with the SEC.)
- 84-3898466 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- REVELATION BIOSCIENCES, INC. (company) — Registrant
- Petra Acquisition Inc. (company) — Former company name
- May 15, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Diego, Calif (location) — Business and mail address city and state
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of the matters voted upon are not provided in this excerpt.
What financial statements and exhibits are being filed?
The filing states 'Financial Statements and Exhibits' are being filed, but the specific content of these documents is not detailed in this excerpt.
When was Revelation Biosciences, Inc. formerly known as Petra Acquisition Inc.?
The date of the name change from Petra Acquisition Inc. to Revelation Biosciences, Inc. was April 23, 2020.
What is the company's primary industry classification?
The company's Standard Industrial Classification is 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where is Revelation Biosciences, Inc. headquartered?
The company's business address is located at 4660 La Jolla Village Drive, Suite 100, San Diego, CA 92122.
Filing Stats: 669 words · 3 min read · ~2 pages · Grade level 13 · Accepted 2024-05-16 16:03:41
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share REVB The Nasdaq Stock Mar
- $12,075.00 — of common stock at an exercise price of $12,075.00 per share REVBW The Nasdaq Stock Ma
Filing Documents
- revb-20240515.htm (8-K) — 60KB
- 0000950170-24-061061.txt ( ) — 212KB
- revb-20240515.xsd (EX-101.SCH) — 48KB
- revb-20240515_htm.xml (XML) — 7KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. At the Annual Meeting of the Company, a total of 614,695 shares of the Company's common stock, being greater than one-third of the 1,632,935 shares of common stock issued and outstanding and entitled to vote as of the record date for the Annual Meeting, were present virtually, or represented by valid proxy at the Annual Meeting, constituting a quorum. The following proposals, each as described further in the Proxy Statement, were voted upon by the stockholders: Proposal 1 – Election of Directors Stockholders approved to elect the two nominees for Class B director named herein to serve until the 2027 Annual Meeting or their successors are duly elected and qualified, based on the votes listed below: Director Nominee For Against Abstain James Rolke 122,822 23,715 6,620 Jess Roper 122,543 27,978 2,636 There were 461,538 broker non-votes regarding the election of directors. Proposal 2 – Approval to increase the number of shares reserved under the Company's 2021 Equity Incentive Plan Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares reserved under the 2021 Equity Incentive Plan from 21,623 to 163,294, based on the votes listed below: For Against Abstain 107,447 42,981 2,729 There were 461,538 broker non-votes regarding this proposal. Proposal 3 – Ratification of the Auditor Stockholders ratified Baker Tilly US, LLP to audit our financial statements for the fiscal year ending December 31, 2024, based on the votes listed below: For Against Abstain 595,879 18,558 258 There were no broker non-votes regarding this proposal.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVELATION BIOSCIENCES, INC. Date: May 16, 2024 By: /s/ Chester S. Zygmont, III Chester S. Zygmont, III Chief Financial Officer (principal financial and accounting officer)